Fmr LLC Has $496,000 Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Fmr LLC grew its position in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 34.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 173,595 shares of the company’s stock after purchasing an additional 44,199 shares during the period. Fmr LLC’s holdings in Organogenesis were worth $496,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in ORGO. Pallas Capital Advisors LLC bought a new stake in Organogenesis during the second quarter worth about $38,000. Delap Wealth Advisory LLC bought a new position in Organogenesis in the 2nd quarter valued at $40,000. Intech Investment Management LLC bought a new stake in shares of Organogenesis during the third quarter worth $43,000. Allspring Global Investments Holdings LLC raised its holdings in shares of Organogenesis by 4,989.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock valued at $44,000 after buying an additional 15,369 shares during the last quarter. Finally, Mackenzie Financial Corp grew its holdings in Organogenesis by 46.1% during the 2nd quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock worth $68,000 after acquiring an additional 7,678 shares during the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

Insider Buying and Selling

In other Organogenesis news, CEO Gary S. Gillheeney sold 41,052 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $3.52, for a total transaction of $144,503.04. Following the transaction, the chief executive officer now owns 3,359,726 shares in the company, valued at approximately $11,826,235.52. This trade represents a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 278,116 shares of company stock valued at $991,190 over the last ninety days. Insiders own 36.90% of the company’s stock.

Organogenesis Price Performance

Shares of ORGO stock opened at $3.24 on Thursday. The firm’s 50 day moving average is $3.45 and its 200-day moving average is $3.01. Organogenesis Holdings Inc. has a 1 year low of $2.16 and a 1 year high of $4.70. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $429.55 million, a price-to-earnings ratio of -54.00 and a beta of 1.73.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.11. The business had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same quarter last year, the business earned $0.02 earnings per share. Sell-side analysts forecast that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.